Cabecera 2019 CBMSO CSIC UAM

Wednesday, 21st August 2019

2018.11.28 adolfo ferrando


Prof. Adolfo Ferrando

Institute of Cancer Genetics
Columbia University, NY, USA





2018 11 28 Adolfo Ferrando MinAdolfo Ferrando es profesor de Pediatría y Patología en la Universidad de Columbia y director del Programa de Desarrollo Linfoide y Malignidad en el Centro Integral de Cáncer Herbert Irving en Nueva York. Se graduó en medicina en la Universidad de Oviedo en 1994 y defendió su tesis doctoral sobre los mecanismos de resistencia a la quimioterapia en el Departamento de Bioquímica y Biología Molecular también en la Universidad de Oviedo en 1999. Tras realizar su residencia en Hematología en el Hospital Central de Asturias, se trasladó al Departamento de Oncología Pediátrica del Instituto de Investigación del Cáncer Dana Farber en Boston, donde inició sus estudios sobre los mecanismos genéticos de la leucemia linfoblástica aguda.

En 2005, el Dr. Ferrando estableció su grupo de investigación en el Instituto de Genética del Cáncer de la Universidad de Columbia, donde ha realizado importantes contribuciones sobre la identificación de factores genéticos y moleculares críticos en la generación de leucemias y linfomas de alto riesgo, en particular, de la leucemia linfobástica aguda de tipo T (T-ALL). En los últimos años, el laboratorio del Dr. Ferrando se ha centrado en la función oncogénica de NOTCH1 en la patogénesis de la T-ALL, estudiando el impacto antileucémico del bloqueo de la señalización inducida por NOTCH1. Estos estudios han descubierto el papel de NOTCH1 como un regulador central de la proliferación de las células leucémicas. Además, el trabajo de su grupo ha permitido identificar los circuitos reguladores de la transcripción controlados por el oncogén TLX1, identificando numerosos genes supresores de tumores implicados en la T-ALL. Asimismo, algunos de sus trabajos más recientes se han centrado en la identificación de nuevos mecanismos genéticos y de señalización que determinan la resistencia a la quimioterapia en la T-ALL.



Adolfo Ferrando is Professor of Pediatrics and Pathology at Columbia University Medical Center, and Director of the Lymphoid Development and Malignancy Program at the Herbert Irving Comprehensive Cancer Center, New York. He obtained his MD degree from University of Oviedo in 1994 and defended his PhD thesis in 1999 on the mechanisms of chemotherapy resistance at the Department of Biochemistry and Molecular Biology, also at University of Oviedo. After completing his residency in Hematology at Hospital Central de Asturias, he joined the Pediatric Oncology Department at Dana Farber Cancer Research Institute in Boston, where initiated his studies in the genetics and mechanisms of acute lymphoblastic leukemia.

In 2005, Dr. Ferrando established his research group at the Institute for Cancer Genetics at Columbia University, where he made major contributions to the identification and targeting of key genetic and molecular drivers of high risk leukemias and lymphomas, particularly, of T-cell acute lymphoblastic leukemia (T-ALL). Over the last years, Dr. Ferrando’s lab has analyzed the oncogenic function of NOTCH1 and the antileukemic properties of blocking NOTCH1 signaling. These studies have uncovered the role of NOTCH1 as a master regulator of leukemia cell growth. In addition, his group has dissected the transcriptional regulatory circuits controlled by the TLX1 oncogene and identified numerous T-ALL tumor suppressor genes. Some of his most recent work has focused on the elucidation of novel signaling and genetic mechanisms driving chemotherapy resistance in T-ALL.


Publicaciones relevantes / Main publications:

  • Dieck CL, Tzoneva G, Forouhar F, Carpenter Z, Ambesi-Impiombato A, Sánchez-Martín M, Kirschner-Schwabe R, Lew S, Seetharaman J, Tong L, Ferrando AA. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell. 2018 Jul 9;34(1):136-147.
  • Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018 Jan 25;553(7689):511-514.
  • Ferrando AA, López-Otín C. Clonal evolution in leukemia. Nat Med. 2017 Oct 6;23(10):1135-1145.
  • Oshima K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, Abate F, Ambesi-Impiombato A, Sanchez-Martin M, Carpenter Z, Penson A, Perez-Garcia A, Eckert C, Nicolas C, Balbin M, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Devidas M, Loh ML, Kirschner-Schwabe R, Palomero T, Rabadan R, Ferrando AA. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11306-11311.
  • Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, Márquez J, Matés JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med. 2015 Oct;21(10):1182-9.
  • Schnell SA, Ambesi-Impiombato A, Sanchez-Martin M, Belver L, Xu L, Qin Y, Kageyama R, Ferrando AA. Therapeutic targeting of HES1 transcriptional programs in T-ALL. Blood. 2015 Apr 30;125(18):2806-14.
  • Belver L, Ferrando AA. Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies.Cancer Discov. 2015 Mar;5(3):234-6.
  • Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med.2014 Oct;20(10):1130-7.

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand


What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: